CN Patent

CN113840606B — 给药kras抑制剂治疗癌症

Assigned to Amgen Inc · Expires 2024-08-30 · 2y expired

What this patent protects

本文提供了向癌症受试者施用KRASG12C抑制剂，即AMG‑510的方法。CA19‑9和CEA生物标志物。

USPTO Abstract

本文提供了向癌症受试者施用KRASG12C抑制剂，即AMG‑510的方法。CA19‑9和CEA生物标志物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113840606B
Jurisdiction
CN
Classification
—
Expires
2024-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.